CompletedNot Applicable

Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients

United States100 participantsStarted 2022-10-31

Plain-language summary

Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient's aged 18 years or older with a confirmed diagnosis of DVT/PE based on imaging or a confirmed diagnosis of ACS requiring heparin therapy Exclusion Criteria: * History of bleeding in the last 30 days * History of HIT * Use of systemic anticoagulants for another indication * Presence of coagulation disorder prior to admission (i.e. hemophilia, sickle cell anemia, etc.)

What they're measuring

Incidents of deviations from protocol

Timeframe: 30 Days

Trial details

NCT IDNCT06096064

SponsorMethodist Health System

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-08-21

View on ClinicalTrials.gov More Unfractionated Heparin trials